Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Idraparinux. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 known ✓ | P00742 | 6/20 | 0.56 |
| ▸ | SERPINC1 | P01008 | 3/20 | 0.85 |
| ▸ | FGF1 | P05230 | 4/20 | 0.57 |
| ▸ | F2 | P00734 | 1/20 | 0.53 |
| ▸ | FGF2 | P09038 | 1/20 | 0.52 |
| ▸ | HPSE | Q9Y251 | 5/20 | 0.48 |
| ▸ | BDNF | P23560 | 2/20 | 0.41 |
| ▸ | PTN | P21246 | 1/20 | 0.41 |
| ▸ | MDK | P21741 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29407493 | 1.00 | SERPINC1 (0.85) | SERPINC1FGF1F10F2FGF2 | |
| Idraparinux SCHEMBL29382311 | 1.00 | SERPINC1 (0.85) | SERPINC1FGF1F10F2FGF2 | |
| SCHEMBL12458587 | 0.93 | SERPINC1 (0.75) | SERPINC1FGF1F10F2FGF2 | |
| SCHEMBL12729453 | 0.92 | SERPINC1 (0.74) | SERPINC1FGF1F10F2FGF2 | |
| SCHEMBL15896273 | 0.88 | SERPINC1 (0.69) | SERPINC1FGF1F10F2FGF2 | |
| SCHEMBL12799309 | 0.87 | SERPINC1 (0.68) | SERPINC1FGF1F10F2FGF2 | |
| SCHEMBL17660081 | 0.86 | SERPINC1 (0.66) | SERPINC1FGF1F10F2FGF2 | |
| SCHEMBL4732494 | 0.86 | SERPINC1 (0.66) | SERPINC1FGF1F10F2FGF2 | |
| SCHEMBL13551204 | 0.86 | SERPINC1 (0.66) | SERPINC1FGF1F10F2FGF2 | |
| SCHEMBL29890443 | 0.85 | SERPINC1 (0.65) | SERPINC1FGF1F10F2FGF2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9873712-B2 | Method of purifying idraparinux sodium | AMPHASTAR PHARMACEUTICALS, INC. (US) | 2018-01-23 | — | — | US | disclosed |
| EP-2414543-B1 | GENETIC MARKERS FOR RISK MANAGEMENT OF ATRIAL FIBRILLATION AND STROKE | DECODE GENETICS EHF (IS) | 2016-10-12 | — | — | EP | disclosed |
| US-20160096856-A1 | METHOD OF PURIFYING IDRAPARINUX SODIUM | AMPHASTAR NANJING PHARMACEUTICALS INC. (CN) | 2016-04-07 | — | — | US | disclosed |
| US-8795963-B2 | Genetic markers for risk management of atrial fibrillation and stroke | DECODE GENETICS EHF. (IS) | 2014-08-05 | — | — | US | disclosed |
| US-8183228-B2 | Anticoagulant antithrombotic dual inhibitors comprising a biotin label | MSD OSS B.V. Netherlands (US) | 2012-05-22 | — | — | US | disclosed |
| EP-2414543-A1 | GENETIC MARKERS FOR RISK MANAGEMENT OF ATRIAL FIBRILLATION AND STROKE | Decode Genetics EHF (IS) | 2012-02-08 | — | — | EP | disclosed |
| US-20120021989-A1 | GENETIC MARKERS FOR RISK MANAGEMENT OF ATRIAL FIBRILLATION AND STROKE | DECODE GENETICS EHF. (IS) | 2012-01-26 | — | — | US | disclosed |
| WO-2010113185-A1 | GENETIC MARKERS FOR RISK MANAGEMENT OF ATRIAL FIBRILLATION AND STROKE | DECODE GENETICS EHF (IS) | 2010-10-07 | — | — | WO | disclosed |
| US-20100029582-A1 | Anticoagulant Antithrombotic Dual Inhibitors Comprising a Biotin Label | MERCK SHARP & DOHME B.V. (NL) | 2010-02-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029582-A1 | Anticoagulant Antithrombotic Dual Inhibitors Comprising a Biotin Label | FGB, F13B, SERPINC1 | F10 42/4885SERPINC1 3/4885FGF1 4650/4885 |
| US-20160096856-A1 | METHOD OF PURIFYING IDRAPARINUX SODIUM | IDUA, REN, SLC26A3 | F10 194/4885SERPINC1 27/4885FGF1 1084/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.